14 completed, 4 recruiting, 2 unknown, 1 active not recruiting. 23 Phase 2, 4 Phase 3, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 23 | Completed 14, Recruiting 4, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Withdrawn 1 |
| Phase 3 | 4 | Completed 3, Recruiting 1 |
| Phase 1 | 3 | Completed 1, Unknown 1, Withdrawn 1 |
Follow Depressive Symptoms: new trials by email Literature Review of Depressive Symptoms trials Research Report on Depressive Symptoms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Electrophysiologic Mechanisms of Ketamine Antidepressant Response Ketamine - Epilepsy, Depressive Symptoms | Phase 2 | Not yet recruiting | Emory University | 37 | 2026-12-01 | 2026-08-17 |
| JAK Signaling in Depression and Cognition in Male Football Players Baricitinib - Depressive Symptoms, Cognitive Symptom | Phase 2 | Recruiting | Emory University | 30 | 2026-10-01 | 2026-09-24 |
| Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients Ketamine (0.5 mg/kg), Normal Saline (0.9% NaCl) - Critical Illness, Depressive Symptoms | Phase 2 | Recruiting | Hospital Italiano de Buenos Aires | 50 | 2026-05-14 | 2026-09-02 |
| Mindfulness Engaged Neurostimulation for Depression (MEND II) Medi-TBS - Depression, Treatment Resistant Depression | Phase 2 | Recruiting | University of California, San Diego | 120 | 2026-05-01 | 2026-05-06 |
| Dog Presence and Oxytocin on Trust Towards Therapists Oxytocin nasal spray, Animal-Assisted Intervention, Placebo - Depressive Symptoms, Human-Animal Interaction | Phase 2 / Phase 3 | Recruiting | Dr. Karin Hediger | 176 | 2024-01-29 | 2024-11-05 |
| Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial CI-581a, CI-581b - Post-acute Sequelae of COVID-19, Depressive Symptoms | Phase 2 | Active not recruiting | New York State Psychiatric Institute | 12 | 2023-03-20 | 2024-07-16 |
| Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD) TNX-601 ER, Placebo - Depression, Depressive Disorder | Phase 2 | Completed | Tonix Pharmaceuticals, Inc. | 132 | 2023-03-02 | 2025-02-17 |
| Cannabidiol for Reduction of Brain Neuroinflammation CBD, Placebo - Back Pain, Depressive Symptoms | Phase 2 | Completed | Massachusetts General Hospital | 69 | 2022-01-04 | 2026-10-15 |
| Mindful Self-Compassion (MSC) for Infertility Related Distress Mindful Self-Compassion - Infertility, Female, Distress, Emotional | Phase 1 / Phase 2 | Completed | University of Regina | 50 | 2021-12-01 | 2025-04-08 |
| Esketamine and Perioperative Depressive Symptoms Esketamine, Normal saline - Depressive Symptoms, Esketamine | Phase 2 / Phase 3 | Completed | Beijing Tiantan Hospital | 435 | 2021-02-19 | 2025-08-01 |
| Cholecalciferol on Depressive Symptoms in Type 2 Diabetes Mellitus Patients Cholecalciferol 4000 IU Oral Capsule, Liquid Filled, Placebo - Diabetes Mellitus, Type 2, Depressive Symptoms | Phase 2 | Unknown | Universitas Indonesia | 90 | 2021-01-18 | 2021-06-08 |
| eIMPACT-DM Pilot Trial: Depression Treatment to Reduce Diabetes Risk Good Days Ahead (GDA), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications - Depression, Major Depressive Disorder | Phase 2 | Completed | Indiana University | 46 | 2020-10-14 | 2023-11-02 |
| Meru Health Ascend Mobile Intervention for Depression in Middle Aged and Older Adults Meru Health Ascend Program - Depression, Depressive Symptoms | Phase 2 / Phase 3 | Completed | Palo Alto Veterans Institute for Research | 70 | 2018-07-12 | 2021-03-10 |
| Stabilizing Behavioral Rhythms to Improve Mental Health Full Package - Depressive Symptoms, Anxiety Symptoms | Phase 2 | Completed | HealthRhythms, Inc. | 128 | 2018-03-01 | 2021-07-01 |
| Mobile Phone App for Depression and Anxiety in Young Men Who Are Attracted to Men Mobile Phone Application - Depressive Symptoms, Anxiety Generalized | Phase 1 / Phase 2 | Withdrawn | Northwestern University | 2017-08-14 | 2017-08-17 | |
| eIMPACT Trial: Modernized Collaborative Care to Reduce the Excess CVD Risk of Older Depressed Patients Beating the Blues (BtB), Problem Solving Treatment in Primary Care (PST-PC), Antidepressant Medications - Depression, Major Depressive Disorder | Phase 2 | Completed | Indiana University | 216 | 2015-07-01 | 2023-10-19 |
| TNS for Major Depressive Disorder: a Phase II Randomized Controlled Trial Trigeminal Nerve Stimulation (TNS) - Depressive Symptoms | Phase 1 / Phase 2 | Unknown | Santa Casa Medical School | 44 | 2014-05-01 | 2015-05-05 |
| Anti-INFLammatory to Address Mood and Endothelial Dysfunction (INFLAMED) Pentoxifylline, Placebo, Standard Treatment - Major Depressive Disorder, Depression | Phase 2 | Completed | Indiana University | 36 | 2012-06-01 | 2015-12-03 |
| Beating the Blues for Your Heart Beating the Blues (BtB), Usual Care - Depression, Depressive Symptoms | Phase 2 | Completed | Indiana University | 29 | 2011-07-01 | 2022-12-29 |
| Cognitive Behavioral Therapy for Patients With an Early Psychosis cognitive behavioral therapy - Psychosis, Schizophrenia | Phase 2 | Completed | Oslo University Hospital | 60 | 2011-01-01 | 2014-10-23 |
Showing 20 of 23. Sign in to see all of them.
Depression (23) · Depressive Disorder, Major (5) · Anxiety Disorders (4) · Cardiovascular Diseases (3) · Coronary Artery Disease (3) · Heart Diseases (3) · Depressive Disorder (2) · Diabetes Mellitus, Type 2 (2) · Dysthymic Disorder (2) · Inflammation (2) · Alzheimer Disease (1) · Back Pain (1) · Bisexuality (1) · Cocaine-Related Disorders (1) · Cognitive Dysfunction (1)
Behavior (23) · Behavioral Symptoms (23) · Mental Disorders (13) · Pathological Conditions, Signs and Symptoms (6) · Mood Disorders (5) · Pathologic Processes (5) · Nervous System Diseases (4) · Arterial Occlusive Diseases (3) · Arteriosclerosis (3) · Brain Diseases (3) · Central Nervous System Diseases (3) · Coronary Disease (3) · Depressive Disorder (3) · Disease Attributes (3) · Endocrine System Diseases (3)
Cognitive Behavioral Therapy (3) · Ketamine (2) · Primary Health Care (2) · Saline Solution (2) · Selective Serotonin Reuptake Inhibitors (2) · Therapeutics (2) · Bupropion (1) · Cannabidiol (1) · Capsules (1) · Cholecalciferol (1) · Esketamine (1) · Gabapentin (1) · Pentoxifylline (1) · Psilocybin (1) · Serotonin and Noradrenaline Reuptake Inhibitors (1)
Indiana University (4) · Emory University (2) · Beijing Tiantan Hospital (1) · Dr. Karin Hediger (1) · Duke University (1) · HealthRhythms, Inc. (1) · Hospital Italiano de Buenos Aires (1) · Johns Hopkins University (1) · Massachusetts General Hospital (1) · New York State Psychiatric Institute (1) · Northwestern University (1) · Oslo University Hospital (1) · Palo Alto Veterans Institute for Research (1) · Santa Casa Medical School (1) · Tonix Pharmaceuticals, Inc. (1)
United States (17) · Argentina (1) · Brazil (1) · Canada (1) · China (1) · Indonesia (1) · Norway (1) · Switzerland (1)
Jesse C Stewart, PhD (2) · Alison Oliveto, PhD (1) · Andrew H Miller, MD (1) · Carl Hacker, MD, PhD (1) · Christine E Gould, PhD (1) · Devang K Sanghavi, M.B.B.S., M.D. (1) · Elias Dakwar, MD (1) · Ellen Frank, PhD (1) · Federico Carini, M.D. (1) · Gregory Sullivan, MD (1) · Ivan A Huespe, M.D., M.P.H. (1) · Jesse C Stewart, Ph.D. (1) · Jesse C. Stewart, Ph.D. (1) · Kate O'Malley, MA (1)
PMID 27909165, PMID 31935529, PMID 35473735, PMID 35917659, PMID 36120713, PMID 36123113, PMID 37209779, PMID 37931480, PMID 39252547, PMID 39639945, PMID 40822596, PMID 40930184, PMID 42119799
2023 (1), K08MH094441 (1), P50DA018197 (1), R01HL122245 (1), R21DK123582 (1), R24MH080827 (1), R44MH113520 (1)